Breaking News! Sansure Biotech’s SARS-CoV-2 Rapid Antigen Test (Self-testing) Obtains CE 1434 Certificate
On April 13, the SARS-CoV-2 Rapid Antigen Test (Self-testing) developed by Sansure Biotech has obtained the CE 1434 certificate, which means that the self-test kit can be distributed in EU countries and countries that recognize the EU CE certification.
SARS-CoV-2 antigen test is an important means of epidemic prevention and control, which can be used as an auxiliary diagnosing method of SARS-CoV-2. Sansure Biotech’s SARS-CoV-2 Rapid Antigen Test (Self-testing) requires no testing instrument, the operation is simple and fast and can be conducted by individuals by collecting nasal swab samples. Test results are available in 15-20 minutes, which is convenient for individuals and families to have a quick test of SARS-CoV-2 virus.
Sansure Biotech’s SARS-CoV-2 Rapid Antigen Test (Self-testing) has obtained the EU CE1434 certificate, indicating that the performance of the Company’s immunodetection product has been recognized by the authorities. This further improves Sansure Biotech’s full-scenario SARS-CoV-2 detection solutions, continuing to contribute to the global epidemic prevention and control.